AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01037673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
Study NCT01037673 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Movement exercises
Description: A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
Study NCT01409460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oburator Nerve block
Description: Use of selective pain block.
Study NCT01409460 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection in pectineus muscle.
Description: Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
Study NCT03454854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intelligent terminal APP
Description: Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
Study NCT02899858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Assessment
Description: Documentation of ASIA A (T2-8) status at Belmont Gait Lab
Study NCT02899858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Total MRI of spine to evaluate condition of spinal cord
Study NCT02899858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IntraSpinal Micro-Stimulation
Description: IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
Study NCT02899858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up clinical exam
Description: All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
Study NCT02899858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Op MRI Scan
Description: An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
Study NCT02899858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up gait assessment
Description: Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
Study NCT04513470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
Study NCT00481845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg daily
Study NCT00481845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg daily
Study NCT00481845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg daily
Study NCT04285333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia iliaca block
Description: ultrasound guided block with 20 mL lidocaine 1.5%
Study NCT04285333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percapsular nerve group block
Description: ultrasound guided block with 20 mL lidocaine 1.5%
Study NCT02594436 — intervention group
Intervention type: DRUG
Intervention: Ingenol mebutate
Description: Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
Study NCT00004029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant viral vaccine therapy
Study NCT00004029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00880256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction
Description: An 8-week course in mindfulness training
Study NCT02640963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
Study NCT02640963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
Study NCT00457496 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive, behavioral, exercise
Description: Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
Study NCT01303055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily : two years
Study NCT01303055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 750 mg
Description: Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %.
Study NCT01618760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Tablet 1 mg
Description: 1 mg tablet once a day
Study NCT01618760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg tablet once a day
Study NCT00697957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive impact exercise
Study NCT01234155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training - Interval Walking
Description: Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
Study NCT01234155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise - Continuous Walking
Description: Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
Study NCT00617877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
Study NCT00617877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
Study NCT01726179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.
Study NCT01726179 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.
Study NCT02680782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: 100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
Study NCT02495948 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Study NCT01902173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study NCT02252172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab IV
Description: Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
Study NCT02252172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
Study NCT02252172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally or intravenously once in a week.
Study NCT02252172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab SC
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Study NCT02495948 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A contact lenses
Study NCT02495948 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide solution
Description: Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
Study NCT02495948 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution
Description: Used for rinsing contact lenses, as needed
Study NCT02022449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management
Description: Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
Study NCT01822002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canalith repositioning maneuver
Study NCT01543347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Antibiotic treatment
Study NCT01481896 — intervention group
Intervention type: DEVICE
Intervention: Metal-on-metal primary total hip arthroplasty (DePuy )
Description: Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
Study NCT00165958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excisional surgery of epidermal cyst
Description: Traditional extirpation of cyst en toto
Study NCT00165958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch incision of epidermal cyst
Description: removal of cyst first with incisional effort with a punch biopsy tool
Study NCT03152240 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study NCT03830216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected insulin pen and smartphone app
Description: The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
Study NCT03830216 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive connected insulin pen without smartphone app
Description: The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
Study NCT02251912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: 10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
Study NCT02251912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
Study NCT02168595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
Study NCT02168595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03790592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trifocal IOL
Description: intraocular lens
Study NCT03325179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread-embedding Therapy
Study NCT02472522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
Study NCT02472522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
Study NCT02173093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Given SC
Study NCT02173093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2Bi-aATC
Description: Given IV
Study NCT01998542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
Study NCT01998542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: autologous tumor-derived chaperone protein mixture
Study NCT01998542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim (ID) injection AlloStim (IV) infusion
Study NCT04055103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monthly feedback, education and linking hospitals
Description: - Give monthly feedback from LROI-data (revision rate \& patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
Study NCT05257512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505
Description: The third-generation ALK TKI
Study NCT03135912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Drug SESC 01
Description: Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
Study NCT03135912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage method of SESC 01, without active ingredients.
Study NCT03135912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: Topical terbinafine hydrochloride cream.
Study NCT02266433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders.
Study NCT02266433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites.
Study NCT01745757 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Treatments received by patients in this study are prescribed in the context of standard care
Study NCT01745757 — intervention group
Intervention type: DRUG
Intervention: paclitaxel
Description: Treatments received by patients in this study are prescribed in the context of standard care
Study NCT04620330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766)
Description: Monotherapy
Study NCT04620330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and Defactinib
Description: Combination therapy
Study NCT04391725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periapical surgery with guided tissue regeneration
Description: periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
Study NCT04391725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery without anyguided tissue regeneration
Description: periapical surgery will be done followed by flap closure
Study NCT04364919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise program
Description: The program incorporated modified yoga movements suitable for pregnant women. The DVD provides an illustration with the written caption, Please take enough water before exercise, and wear loose and comfortable clothes in a suitable environment. If you feel tired, stop exercising immediately. The DVD's narrator then says, Now you are ready to prepare a comfortable, solid chair with a chair back. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercises were developed as a progressive program in order to achieve the goals of strength-conditioning, moderate-intensity exercise (ACOG, 2015).
Study NCT03324360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: MRI with Hyperpolarized 13C-Pyruvate Injection
Study NCT04741269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Find a link between lack of knee flexion and meniscal posterior luxation fixed
Description: Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift.
Study NCT02602223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placing Amnion chorion membrane over grafted site
Description: Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed